Eye Lens Maker STAAR Surgical Expects Q1 Sales To Beat Consensus
Eye Lens Maker STAAR Surgical Expects Q1 Sales To Beat Consensus
Thursday, STAAR Surgical Company (NASDAQ:STAA) reported preliminary net sales for the first quarter of 2024 of more than $77 million versus the consensus of $72.13 million, with U.S. ICL sales expected to be $5 million for the quarter.
週四，STAAR外科公司（納斯達克股票代碼：STAA）報告稱，2024年第一季度的初步淨銷售額超過7700萬美元，而市場預期爲7,213萬美元，本季度美國ICL的銷售額預計爲500萬美元。
This represents the company's highest quarterly ICL sales in the U.S. since the company obtained U.S. FDA approval for the EVO ICL in March 2022.
這是該公司自2022年3月獲得美國食品藥品管理局對EVO ICL的批准以來在美國最高的季度ICL銷售額。
"STAAR is off to a solid start in 2024 as illustrated by our preliminary first quarter results, including a record quarter in the U.S.," said Tom Frinzi, President and CEO.
總裁兼首席執行官湯姆·弗林齊表示：“我們的第一季度初步業績表明，包括創紀錄的美國季度業績，STAAR在2024年有了一個良好的開端。”
"U.S. ICL sales were up approximately 20% sequentially to $5 million in the first quarter, which reflects early signs of our increased market focus. EMEA ICL sales were up approximately 11% year over year and ICL sales in our APAC region were up approximately 9%, including approximately 10% growth in China.
“美國ICL銷售額在第一季度連續增長了約20％，達到500萬美元，這反映了我們越來越關注市場的早期跡象。歐洲、中東和非洲ICL的銷售額同比增長了約11％，亞太地區的ICL銷售額增長了約9％，其中包括中國約10％的增長。
We are pleased by the first quarter performance across all major geographies and will provide further detail on our results and outlook during our upcoming earnings call, but at this time we believe our fiscal 2024 net sales can be at the higher end of our previously announced outlook range of $335 million to $340 million."
我們對所有主要地區的第一季度表現感到滿意，並將在即將舉行的業績電話會議上提供有關業績和前景的更多細節，但目前我們認爲我們的2024財年淨銷售額可能處於先前公佈的3.35億美元至3.4億美元的展望區間的較高水平。”
Cash, cash equivalents, and investments available for sale were approximately $248 million, and accounts receivable were approximately $70 million as of March 29, 2024.
截至2024年3月29日，可供出售的現金、現金等價物和投資約爲2.48億美元，應收賬款約爲7,000萬美元。
Needham writes that if the seasonal pattern of 2024 follows that of 2022 and 2023, it's anticipated that 2024 revenues will likely approach $355 million.
尼德姆寫道，如果2024年的季節性模式遵循2022年和2023年的季節性模式，預計2024年的收入將可能接近3.55億美元。
Despite this, achieving STAAR Surgical's revenue target for 2026 seems challenging, especially considering the necessary acceleration.
儘管如此，實現STAAR Surgical的2026年的收入目標似乎具有挑戰性，尤其是考慮到必要的加速。
During a recent expert call, a doctor mentioned no expectation for an increase in their ICL mix.
在最近的一次專家電話會議上，一位醫生提到，他們的ICL組合沒有增加的預期。
While Needham analysts see the 2024 guidance as cautious, and anticipate a gradual domestic growth. Needham maintains the Hold rating.
而Needham分析師則認爲2024年的指引是謹慎的，並預計國內將逐步增長。Needham 維持持有評級。
Price Action: STAA shares are up 17.3% at $45.83 on the last check Thursday.
價格走勢：在週四的最後一次支票中，STAA股價上漲17.3％，至45.83美元。
Photo by Gerax Sotelo on Unsplash
由 Gerax Sotelo 在 Unsplash 上拍攝的照片
譯文內容由第三人軟體翻譯。